Several therapeutic strategies have been explored to target aberrant cytosolic localization of mutant NPM1 in AML including inhibitors of nuclear export such as leptomycin B or selinexor [41,42], which has interestingly shown clinical activity in a phase I trial in refractory non-Hodgkin lymphoma [43]. This evidence concerns the gene NPM1 and acute myeloid leukemia.